|
Market Cap (25-Jun) $7,649,007 (1,598th) |
Close (30-Jun) $0.024 |
Volume (30-Jun) 2,170,184 |
Shortsold (2-Feb) 3,141 (0.00%) (662nd) |
|
52w High $0.008 |
52w Low $0.002 |
P/E - |
EPS 0 |
1AD released this announcement to the ASX on 20 October 2022, 8:10. The announcement is not marked as price sensitive, and is 25 page(s) in length and 744.87kb in size.
You can view all announcements from 1AD and see how they appear on a price chart on the announcements page.
| Other Recent Announcements from 1AD | |
|---|---|
| AD-214 clinical trial approval | 29 June 2023, 8:21 |
| Change in substantial holding | 31 May 2023, 13:30 |
| Change in substantial holding | 31 May 2023, 9:34 |
| Letter to Shareholders, Notice of AGM & Proxy Form | 20 October 2022, 8:10 |
| 1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer | 13 October 2022, 8:19 |
| Notification of cessation of securities - 1AD | 10 October 2022, 13:52 |
| R&D Tax Incentive Refund received | 4 October 2022, 9:39 |
You must be logged in to post a reply.
AdAlta 